LAVA Therapeutics Analyst Ratings
LAVA Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/23/2023 | 227.87% | HC Wainwright & Co. | $9 → $6 | Maintains | Buy |
| 06/15/2023 | 227.87% | JMP Securities | → $6 | Reiterates | Market Outperform → Market Outperform |
| 06/12/2023 | 391.8% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 06/09/2023 | 227.87% | JMP Securities | → $6 | Reiterates | Market Outperform → Market Outperform |
| 04/13/2023 | 391.8% | HC Wainwright & Co. | → $9 | Reiterates | → Buy |
| 02/17/2023 | 391.8% | HC Wainwright & Co. | → $9 | Reiterates | → Buy |
| 10/25/2022 | 391.8% | HC Wainwright & Co. | → $9 | Initiates Coverage On | → Buy |
| 09/27/2022 | 1430.05% | SVB Leerink | $25 → $28 | Maintains | Outperform |
| 09/15/2022 | 227.87% | JMP Securities | → $6 | Initiates Coverage On | → Market Outperform |
| 05/18/2022 | 1266.12% | SVB Leerink | $23 → $25 | Maintains | Outperform |
| 11/16/2021 | 992.9% | SVB Leerink | $24 → $20 | Maintains | Outperform |
| 08/17/2021 | 1211.48% | SVB Leerink | $26 → $24 | Maintains | Outperform |
| 04/19/2021 | 1156.83% | Jefferies | → $23 | Initiates Coverage On | → Buy |
| 04/19/2021 | 1102.19% | JP Morgan | → $22 | Initiates Coverage On | → Overweight |
| 04/19/2021 | 1320.77% | SVB Leerink | → $26 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/23/2023 | 227.87% | HC Wainwright & Co. | 9 美元 → 6 美元 | 维护 | 购买 |
| 06/15/2023 | 227.87% | JMP 证券 | → 6 美元 | 重申 | 市场跑赢大盘 → 市场跑赢大盘 |
| 06/12/2023 | 391.8% | HC Wainwright & Co. | → 9 美元 | 重申 | 购买 → 购买 |
| 06/09/2023 | 227.87% | JMP 证券 | → 6 美元 | 重申 | 市场跑赢大盘 → 市场跑赢大盘 |
| 04/13/2023 | 391.8% | HC Wainwright & Co. | → 9 美元 | 重申 | → 购买 |
| 02/17/2023 | 391.8% | HC Wainwright & Co. | → 9 美元 | 重申 | → 购买 |
| 10/25/2022 | 391.8% | HC Wainwright & Co. | → 9 美元 | 启动覆盖开启 | → 购买 |
| 09/27/2022 | 1430.05% | SVB Leerink | 25 美元 → 28 美元 | 维护 | 跑赢大盘 |
| 2022 年 9 月 15 日 | 227.87% | JMP 证券 | → 6 美元 | 启动覆盖开启 | → 市场跑赢大盘 |
| 05/18/2022 | 1266.12% | SVB Leerink | 23 美元 → 25 美元 | 维护 | 跑赢大盘 |
| 11/16/2021 | 992.9% | SVB Leerink | 24 美元 → 20 美元 | 维护 | 跑赢大盘 |
| 2021 年 8 月 17 日 | 1211.48% | SVB Leerink | 26 美元 → 24 美元 | 维护 | 跑赢大盘 |
| 2021 年 4 月 19 日 | 1156.83% | 杰富瑞 | → 23 美元 | 启动覆盖开启 | → 购买 |
| 2021 年 4 月 19 日 | 1102.19% | 摩根大通 | → 22 美元 | 启动覆盖开启 | → 超重 |
| 2021 年 4 月 19 日 | 1320.77% | SVB Leerink | → 26 美元 | 启动覆盖开启 | → 跑赢大盘 |
What is the target price for LAVA Therapeutics (LVTX)?
LAVA Therapeutics（LVTX）的目标价格是多少？
The latest price target for LAVA Therapeutics (NASDAQ: LVTX) was reported by HC Wainwright & Co. on August 23, 2023. The analyst firm set a price target for $6.00 expecting LVTX to rise to within 12 months (a possible 227.87% upside). 9 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年8月23日公布了LAVA Therapeutics（纳斯达克股票代码：LVTX）的最新目标股价。该分析公司将目标股价定为6.00美元，预计LVTX将在12个月内上涨至227.87％（可能上涨227.87％）。去年有9家分析公司公布了评级。
What is the most recent analyst rating for LAVA Therapeutics (LVTX)?
LAVA Therapeutics（LVTX）的最新分析师评级是多少？
The latest analyst rating for LAVA Therapeutics (NASDAQ: LVTX) was provided by HC Wainwright & Co., and LAVA Therapeutics maintained their buy rating.
LAVA Therapeutics（纳斯达克股票代码：LVTX）的最新分析师评级由HC Wainwright & Co. 提供，LAVA Therapeutics维持买入评级。
When is the next analyst rating going to be posted or updated for LAVA Therapeutics (LVTX)?
LAVA Therapeutics（LVTX）的下一次分析师评级何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of LAVA Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for LAVA Therapeutics was filed on August 23, 2023 so you should expect the next rating to be made available sometime around August 23, 2024.
分析师在进行了广泛的研究后得出了股票评级，包括阅读公开财务报表、与LAVA Therapeutics的高管和客户交谈以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应获得4个评级。LAVA Therapeutics的最后一次评级是在2023年8月23日提交的，因此你应该预计下一个评级将在2024年8月23日左右公布。
Is the Analyst Rating LAVA Therapeutics (LVTX) correct?
分析师对LAVA Therapeutics（LVTX）的评级正确吗？
While ratings are subjective and will change, the latest LAVA Therapeutics (LVTX) rating was a maintained with a price target of $9.00 to $6.00. The current price LAVA Therapeutics (LVTX) is trading at is $1.83, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的LAVA Therapeutics（LVTX）评级保持不变，目标股价为9.00美元至6.00美元。LAVA Therapeutics（LVTX）目前的交易价格为1.83美元，超出了分析师的预测区间。